Show simple item record

dc.contributor.authorMasin, Mark
dc.contributor.authorVazquez, Jessica
dc.contributor.authorRossi, Simona
dc.contributor.authorGroeneveld, Svenja
dc.contributor.authorSamson, Natasha
dc.contributor.authorSchwalie, Petra C
dc.contributor.authorDeplancke, Bart
dc.contributor.authorMoradpour, Darius
dc.contributor.authorOliver, Trudy
dc.contributor.authorMeylan, Etienne
dc.contributor.authorFrawley, Laura Elizabeth
dc.contributor.authorGouttenoire, Jerome
dc.date.accessioned2014-09-05T12:37:48Z
dc.date.available2014-09-05T12:37:48Z
dc.date.issued2014-07
dc.date.submitted2014-03
dc.identifier.issn2049-3002
dc.identifier.urihttp://hdl.handle.net/1721.1/89189
dc.description.abstractBackground: Alterations in glucose metabolism and epithelial-mesenchymal transition (EMT) constitute two important characteristics of carcinoma progression toward invasive cancer. Despite an extensive characterization of each of them separately, the links between EMT and glucose metabolism of tumor cells remain elusive. Here we show that the neuronal glucose transporter GLUT3 contributes to glucose uptake and proliferation of lung tumor cells that have undergone an EMT. Results: Using a panel of human non-small cell lung cancer (NSCLC) cell lines, we demonstrate that GLUT3 is strongly expressed in mesenchymal, but not epithelial cells, a finding corroborated in hepatoma cells. Furthermore, we identify that ZEB1 binds to the GLUT3 gene to activate transcription. Importantly, inhibiting GLUT3 expression reduces glucose import and the proliferation of mesenchymal lung tumor cells, whereas ectopic expression in epithelial cells sustains proliferation in low glucose. Using a large microarray data collection of human NSCLCs, we determine that GLUT3 expression correlates with EMT markers and is prognostic of poor overall survival. Conclusions: Altogether, our results reveal that GLUT3 is a transcriptional target of ZEB1 and that this glucose transporter plays an important role in lung cancer, when tumor cells loose their epithelial characteristics to become more invasive. Moreover, these findings emphasize the development of GLUT3 inhibitory drugs as a targeted therapy for the treatment of patients with poorly differentiated tumors.en_US
dc.publisherBioMed Central Ltden_US
dc.relation.isversionofhttp://dx.doi.org/10.1186/2049-3002-2-11en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0en_US
dc.sourceBioMed Central Ltden_US
dc.titleGLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung canceren_US
dc.typeArticleen_US
dc.identifier.citationMasin, Mark, Jessica Vazquez, Simona Rossi, Svenja Groeneveld, Natasha Samson, Petra C Schwalie, Bart Deplancke, et al. “GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.” Cancer & Metabolism 2, no. 1 (2014): 11.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorFrawley, Laura Elizabethen_US
dc.relation.journalCancer & Metabolismen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2014-08-05T15:12:32Z
dc.language.rfc3066en
dc.rights.holderMark Masin et al.; licensee BioMed Central Ltd.
dspace.orderedauthorsMasin, Mark; Vazquez, Jessica; Rossi, Simona; Groeneveld, Svenja; Samson, Natasha; Schwalie, Petra C; Deplancke, Bart; Frawley, Laura E; Gouttenoire, Jerome; Moradpour, Darius; Oliver, Trudy G; Meylan, Etienneen_US
dc.identifier.orcidhttps://orcid.org/0000-0001-5843-0976
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record